Ankyra appoints Sailaja Battula, PhD as chief scientific officer (CSO)

by ankyratx1dev | Dec 15, 2025

Ankyra appoints Sailaja Battula, PhD as chief scientific officer (CSO) December 15, 2025 (Cambridge, MA) – Ankyra Therapeutics, a clinical-stage biotechnology company pioneering anchored drug conjugate technology for cancer and other diseases, today announced Sailaja...

Ankyra Therapeutics Announces First Patient Dosed in Phase 1b Trial Evaluating First-in-Class Anchored Immunotherapy in Combination with Immune Checkpoint Blockade in Patients with Lung Cancer

by ankyratx1dev | Nov 17, 2025

Ankyra Therapeutics Announces First Patient Dosed in Phase 1b Trial Evaluating First-in-Class Anchored Immunotherapy in Combination with Immune Checkpoint Blockade in Patients with Lung Cancer  Phase 1b LANTERN clinical study is assessing tolododekin alfa, anchored...

Ankyra announces publication of Phase 1 clinical data, and will present at the Society for Immunotherapy of Cancer (SITC) annual meeting

by ankyratx1dev | Nov 4, 2025

Ankyra announces publication of Phase 1 clinical data, and will present at the Society for Immunotherapy of Cancer (SITC) annual meeting Initial Phase 1 data, recently published in Nature Communications, demonstrated clinical activity with no dose limiting toxicity in...

Ankyra Therapeutics Announces Phase 1 Clinical Data at the 2025 AACR Annual Meeting and the first patient has been dosed with tolododekin alfa and cemiplimab

by ankyratx1dev | Apr 28, 2025

Ankyra Therapeutics announced preliminary clinical data today from Part 1 of their Phase 1 ANCHOR study evaluating an anchored IL-12 drug conjugate, tolododekin alfa, as monotherapy in patients with solid tumors Ankyra also announced the first patient has been dosed...

Ankyra Therapeutics Announces Expansion of Existing Collaboration to advance IL-12 Anchored Drug Conjugate in Patients with Lung Cancer

by ankyratx1dev | Jan 10, 2025

JANUARY 10, 2025 (CAMBRIDGE, MA) – Ankyra Therapeutics, a clinical-stage biotech company developing anchored drug conjugates for the treatment of cancer, today announced an expanded collaboration with Johnson & Johnson* to advance the clinical development of...